On Friday, Novo Nordisk A/S (NYSE:NVO) released headline results from the REDEFINE 1 Phase 3 trial in the global REDEFINE program.When evaluating the effects of treatment if all people adhered to treatment, people treated with CagriSema achieved a weight loss of 22.7% after 68 weeks compared to a reduction of 11.8% with cagrilintide 2.4 mg, 16.1% with semaglutide 2.4 mg and 2.3% with placebo alone.In November, Novo Nordisk said its hybrid drug, CagriSema, aims to reduce weight by 25% without added side effects.William Blair points out that Novo Nordisk didn’t provide detailed tolerability data in its press release, making it hard to compare their treatment with Eli Lilly’s Zepbound directly. However, only 57% of patients could increase their …Full story available on Benzinga.com
Source :
For further details, visit: https://www.benzinga.com/24/12/42627437/whats-going-on-with-amgen-stock-on-friday
